Predictors of hyperkalemia risk after hypertension control with aldosterone blockade according to the presence or absence of chronic kidney disease

Nephron - Clinical Practice

Volumn 128, Issue , 2014, Pages 381-386

  Gwoo, Sangeon ^a   Kim, Ye Na ^a   Shin, Ho Sik ^a   Jung, Yeon Soon ^a   Rim, Hark ^a  

^a Kosin University College of Medicine   (South Korea)

Author keywords

Aldosterone blockade; Chronic kidney disease; Hyperkalemia; Hypertension; Spironolactone

Indexed keywords

ALDOSTERONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; SPIRONOLACTONE; MINERALOCORTICOID ANTAGONIST;

AGED; ARTICLE; BLOOD PRESSURE MONITORING; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERKALEMIA; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RISK ASSESSMENT; CHEMICALLY INDUCED; CHRONIC KIDNEY FAILURE; COMPLICATION; KIDNEY FUNCTION TEST; MIDDLE AGED;

AGED; ANTIHYPERTENSIVE AGENTS; FEMALE; HUMANS; HYPERKALEMIA; HYPERTENSION; INCIDENCE; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; SPIRONOLACTONE;

EID: 84922935508     PISSN: None     EISSN: 16602110     Source Type: Journal    
DOI: 10.1159/000369138     Document Type: Article

References (22)

1. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J: The effect of spironolactone on morbidity and mortality in patients with severe heart failure-Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717.
2. Pitt B, Reicheck N, Willenbrock R, Zannad F, Phillips RA, Roniker B, Kleiman J, Kruase S, Burns D, Williams GH: Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-Left Ventricular Hypertrophy Study. Circulation 2003; 108:1831-1838.
3. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Klei-man J, Gatlin M; Eplerenone Post-Acute Myo-cardial Infarction Heart Failure Efficacy and Survival Study Investigators: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:1309-1321.
4. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, Sever PS, Thom SM; BHS Guidelines Working Party, for the British Hypertension Society: British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004; 328:634-640.
5. Schepkens H, Vanholder R, Billiouw JM, La-meire N: Life-threatening hyperkalemia during combined therapy with angiotensin-con-verting enzyme inhibitors and spironolac-tone: an analysis of 25 cases. Am J Med 2001; 110:438-441.
6. Cruz CS, Cruz AA, Marcilio de Souza CA: Hyperkalaemia in congestive heart failure patients using ACE inhibitors and spironolac-tone. Nephrol Dial Transplant 2003; 18:1814-1819.
7. Bomback AS, Klemmer PJ: The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 2007; 3:486-492.
8. Bomback AS, Kshirsager AV, Amamoo MA, Klemmer PJ: Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis 2008; 51: 199-211.
9. Bianchi S, Bigazzi R, Campese VM: Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 2006; 70:2116-2123.
10. Chrysostomou A, Pedagogos E, MacGregor L, Becker GJ: Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angio-tensin II receptor blocker. Clin J Am Soc Nephrol 2006; 1:256-262.
11. van den Meiracker AH, Baggen RG, Pauli S, Lindemans A, Vulto AG, Poldermans D, et al: Spironolactone in type 2 diabetic nephropa-thy: effects on proteinuria, blood pressure and renal function. J Hypertens 2006; 24:2285-2292.
12. Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF: Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-Analy-sis. Clin J Am Soc Nephrol 2009; 4:542-551.
13. Bomback AS, Kshirsagar AV, Klemmer PJ: Renal aspirin: will all patients with chronic kidney disease one day take spironolactone? Nat Clin Pract Nephrol 2009; 5:74-75.
14. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation-Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461-470.
15. Chrysostomou A, Becker G: Spironolactone in addition to ACE inhibition to reduce pro-teinuria in patients with chronic renal disease. N Engl J Med 2001; 345:925-926.
16. Sato A, Hayashi K, Naruse M, Saruta T: Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003; 41:64-68.
17. Edwards NC, Steeds RP, Chue CD, Stewart PM, Ferro CJ, Townend JN: The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease. Br J Clin Pharmacol 2012; 73:447-454.
18. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA: Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351:543-551.
19. Wei L, Struthers AD, Fahey T, Watson AD, Macdonald TM: Spironolactone use and renal toxicity: population based longitudinal analysis. BMJ 2010; 340:c1768.
20. Rossignol P, Cleland JG, Bhandari S, Tala S, Gustafsson F, Fay R, et al: Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myo-cardial Infarction Heart Failure Efficacy and Survival Study. Circulation 2012; 125:271-279.
21. Bakris GL, Weir MR: Angiotensin-converting enzyme inhibitor-Associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000; 160:685-693.
22. Pitt B: Pharmacotherapy: cardiovascular effects of aldosterone blockade in CKD. Nat Rev Cardiol 2009; 6:679-680.